UBS raises Madrigal Pharmaceuticals stock price target on F4 trial outlook
UBS raised its price target for Madrigal Pharmaceuticals (MDGL) to $735 from $669, citing a higher probability of success for its F4 program. The stock is currently trading at $452.12, down 22% year-to-date, but analysts maintain a Strong Buy consensus. The company reported Q2 2026 net sales of $364.3 million for Rezdiffra, up 71% year-over-year, but faced a wider net loss and rising expenses. Multiple analysts have adjusted their price targets and ratings for MDGL.
How this was made
The 30-second read
Why it matters
The upgrade may attract new buying interest and support the stock price.
Market read
Analyst price target change is a fresh catalyst for MDGL, offering a short‑term trading edge.
What to watch
Potential regulatory delays or competition in the same therapeutic area.
Background
UBS adjusted its valuation model for Madrigal Pharmaceuticals after reviewing the F4 Outcomes trial data.
Ticker impact
UBS raised MDGL price target to $735 and increased F4 program success probability to 60% after analyzing the F4 Outcomes trial.
likely upward pressure as investors price in higher trial success odds
The PT increase and higher PoS reflect fresh positive data, which typically drives buying interest.
Market effects
Biotech sector may see modest uplift as trial optimism spreads.
U.S. biotech stocks could benefit from the analyst upgrade.
Limited to investors tracking US-listed biotech firms.
Counterpoint
Some investors may view the PT hike as premature without confirmatory Phase 3 data.
Key entities
- CompanyMadrigal Pharmaceuticals
Biopharmaceutical company developing the F4 program.
- AnalystUBS
Investment bank providing the price target revision.
